CA2251331A1 - Calcilytic compounds - Google Patents
Calcilytic compoundsInfo
- Publication number
- CA2251331A1 CA2251331A1 CA002251331A CA2251331A CA2251331A1 CA 2251331 A1 CA2251331 A1 CA 2251331A1 CA 002251331 A CA002251331 A CA 002251331A CA 2251331 A CA2251331 A CA 2251331A CA 2251331 A1 CA2251331 A1 CA 2251331A1
- Authority
- CA
- Canada
- Prior art keywords
- calcilytic compounds
- compounds
- calcilytic
- receptor activity
- calcium receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Abstract
The present invention features calcilytic compounds. "Calcilytic compounds"
refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.
refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62960896A | 1996-04-09 | 1996-04-09 | |
US08/629,608 | 1996-04-09 | ||
US3226396P | 1996-12-03 | 1996-12-03 | |
US60/032,263 | 1996-12-03 | ||
PCT/US1997/005558 WO1997037967A1 (en) | 1996-04-09 | 1997-04-04 | Calcilytic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2251331A1 true CA2251331A1 (en) | 1997-10-16 |
CA2251331C CA2251331C (en) | 2009-06-09 |
Family
ID=26708193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002251331A Expired - Lifetime CA2251331C (en) | 1996-04-09 | 1997-04-04 | Calcilytic compounds |
Country Status (19)
Country | Link |
---|---|
US (2) | US6022894A (en) |
EP (1) | EP0901459B1 (en) |
JP (1) | JP2001501584A (en) |
CN (1) | CN1254465C (en) |
AR (1) | AR008586A1 (en) |
AT (1) | ATE298739T1 (en) |
AU (1) | AU726659B2 (en) |
BR (1) | BR9708632A (en) |
CA (1) | CA2251331C (en) |
CO (1) | CO4820431A1 (en) |
DE (1) | DE69733649T2 (en) |
EA (1) | EA002984B1 (en) |
HK (1) | HK1018899A1 (en) |
IL (1) | IL126458A (en) |
NZ (1) | NZ332068A (en) |
PL (1) | PL191027B1 (en) |
SA (1) | SA97180135B1 (en) |
SG (1) | SG99290A1 (en) |
WO (1) | WO1997037967A1 (en) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4426245A1 (en) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-phenyl-3-dimethylamino-propane compounds with pharmacological activity |
US7202261B2 (en) * | 1996-12-03 | 2007-04-10 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
UY24949A1 (en) * | 1997-04-08 | 2001-04-30 | Smithkline Beecham Corp | CALCILITE COMPOUNDS |
WO1999038500A2 (en) * | 1998-01-30 | 1999-08-05 | The Brigham And Women's Hospital, Inc. | The human calcium-sensing receptor in the detection and treatment of cancer |
US7262280B1 (en) | 1998-04-03 | 2007-08-28 | Nps Pharmaceuticals, Inc. | G-protein fusion receptors and constructs encoding same |
PE20000415A1 (en) | 1998-04-08 | 2000-05-21 | Smithkline Beecham Corp | CALCILITIC COMPOUNDS |
CA2245903A1 (en) | 1998-09-28 | 2000-03-28 | Mcgill University | Use of pex in the treatment of metabolic bone diseases |
PE20001456A1 (en) * | 1999-02-02 | 2001-01-28 | Smithkline Beecham Corp | CALCIOLYTIC COMPOUNDS |
ECSP003590A (en) * | 1999-07-31 | 2002-02-25 | Smithkline Beecham Corp | CALCIOLITIC COMPOUNDS |
US20030018203A1 (en) * | 2002-07-17 | 2003-01-23 | Largo Maria Amparo | Calcilytic compounds |
AR030684A1 (en) * | 2000-01-24 | 2003-09-03 | Smithkline Beecham Corp | CALCILITICAL COMPOUNDS, USE OF SUCH COMPOUNDS IN THE MANUFACTURE OF MEDICINES, AND USEFUL INTERMEDIARIES IN THE PREPARATION OF SUCH COMPOUNDS |
JP2004509077A (en) * | 2000-07-21 | 2004-03-25 | スミスクライン・ビーチャム・コーポレイション | Calcilytic compound |
FR2812875B1 (en) | 2000-08-08 | 2003-12-12 | Centre Nat Rech Scient | NOVEL DIAMINES HAVING CASR MODULATING ACTIVITY AND THEIR METHOD OF PREPARATION |
CA2418794C (en) | 2000-08-11 | 2009-11-24 | Japan Tobacco, Inc. | Calcium receptor antagonists |
JP2004514659A (en) * | 2000-10-25 | 2004-05-20 | スミスクライン・ビーチャム・コーポレイション | Calcilytic compound |
JP4594623B2 (en) | 2002-04-12 | 2010-12-08 | シェーリング コーポレイション | G protein-coupled receptor ligand and method |
US6908935B2 (en) | 2002-05-23 | 2005-06-21 | Amgen Inc. | Calcium receptor modulating agents |
US7176322B2 (en) | 2002-05-23 | 2007-02-13 | Amgen Inc. | Calcium receptor modulating agents |
FR2847250B1 (en) * | 2002-11-15 | 2006-09-22 | Oreal | COMPOSITION, IN PARTICULAR COSMETIC, COMPRISING SECONDARY OR TERTIARY AMINE |
UY28089A1 (en) * | 2002-11-26 | 2004-06-30 | Smithkline Beecham Corp | CALCILITICAL COMPOUNDS |
US7105537B2 (en) | 2003-01-28 | 2006-09-12 | Bristol-Myers Squibb Company | 2-substituted cyclic amines as calcium sensing receptor modulators |
US7205322B2 (en) | 2003-02-12 | 2007-04-17 | Bristol-Myers Squibb Company | Thiazolidine compounds as calcium sensing receptor modulators |
AU2004232604C1 (en) * | 2003-04-23 | 2008-06-05 | Japan Tobacco Inc. | CaSR antagonists |
US7265145B2 (en) * | 2003-05-28 | 2007-09-04 | Bristol-Myers Squibb Company | Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method |
CA2527203C (en) | 2003-05-28 | 2010-08-17 | Japan Tobacco Inc. | Casr antagonist |
WO2005065050A2 (en) | 2003-12-25 | 2005-07-21 | Asahi Kasei Pharma Corporation | Bicyclic compound |
US20080234370A1 (en) * | 2004-02-06 | 2008-09-25 | Marquis Robert W | Calcilytic Compounds |
US7531518B2 (en) * | 2004-05-14 | 2009-05-12 | Unigene Laboratories Inc. | Method for fostering bone formation and preservation |
US7648965B2 (en) * | 2004-05-14 | 2010-01-19 | Unigene Laboratories Inc. | Method for fostering bone formation and preservation |
PT1757582E (en) | 2004-05-28 | 2016-03-04 | Mitsubishi Tanabe Pharma Corp | Arylalkylamines and process for production thereof |
US20080069814A1 (en) * | 2005-01-05 | 2008-03-20 | Novacea, Inc. | Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof |
KR20080028860A (en) * | 2005-04-22 | 2008-04-02 | 노바세아, 인크. | Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin d compounds or mimics thereof |
FR2885129B1 (en) * | 2005-04-29 | 2007-06-15 | Proskelia Sas | NOVEL DERIVATIVES OF UREEE SUBSTITUTED WITH THIAZOLE OR BENZOTHIAZOLE, PROCESS FOR THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THE USE THEREOF |
US20060293667A1 (en) * | 2005-05-19 | 2006-12-28 | Agnes Vignery | Bone implant device and methods of using same |
JP5244597B2 (en) | 2005-09-02 | 2013-07-24 | アムジエン・インコーポレーテツド | Method for regulating intestinal fluid balance using calcilytic or calcimimetic compounds |
EP1965805B1 (en) | 2005-11-25 | 2009-12-02 | Galapagos SAS | Urea derivatives useful as calcium receptor modulators |
WO2009055631A1 (en) * | 2007-10-25 | 2009-04-30 | Smithkline Beecham Corporation | Calcilytic compounds |
CA2726610C (en) * | 2008-06-05 | 2015-05-05 | Asahi Kasei Pharma Corporation | Sulfonamide compounds and use thereof |
EP2196461A1 (en) | 2008-12-15 | 2010-06-16 | Bayer CropScience AG | 4-Amino-1,2,3-benzoxathiazine-derivatives as pesticides |
WO2010103429A1 (en) | 2009-03-10 | 2010-09-16 | Pfizer Inc. | 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists |
GB201217330D0 (en) | 2012-09-28 | 2012-11-14 | Univ Cardiff | Therapeutic for treating inflammatory lung disorders |
CN103601645B (en) * | 2013-11-07 | 2016-05-25 | 上海适济生物科技有限公司 | The preparation method of 1-(phenethyl amino) propane-2-alcohol compound or its salt |
WO2019153216A1 (en) * | 2018-02-09 | 2019-08-15 | 北京梅尔森医药技术开发有限公司 | Substituted arylamino alcohol compound, preparation method therefor, and application thereof |
BR112022010802A2 (en) * | 2019-12-05 | 2022-08-23 | Syngenta Crop Protection Ag | ONE-STEP PROCESS FOR THE PREPARATION OF PHENYLETHYLAMINE DERIVATIVES |
CN116199605A (en) * | 2023-02-27 | 2023-06-02 | 上海睿腾医药科技有限公司 | Synthesis method of 5-chloro-2-hydroxy-dimethylbenzenesulfonamide |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE298506C (en) * | ||||
GB1129072A (en) * | 1966-02-01 | 1968-10-02 | Ici Ltd | Benzofuran and indole derivatives |
GB1058822A (en) * | 1963-07-30 | 1967-02-15 | Ici Ltd | 3-amino-2-hydroxypropoxy heterocyclic derivatives |
GB1199037A (en) * | 1967-09-27 | 1970-07-15 | Ici Ltd | Alkanolamine Derivatives |
ES410417A1 (en) * | 1973-01-08 | 1976-01-01 | Andreu Sa Dr | Procedure for the obtaining of aminoalcohols derived from p-acetamidophenol. (Machine-translation by Google Translate, not legally binding) |
SE388849B (en) * | 1974-02-14 | 1976-10-18 | Haessle Ab | PROCEDURE FOR THE PREPARATION OF NEW AMINES WITH BETA RECEPTOR STIMULATING EFFECTS |
DE2530613A1 (en) * | 1974-11-01 | 1976-05-06 | Haessle Ab | AMINE DERIVATIVES, PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THEM |
US4067904A (en) * | 1975-12-19 | 1978-01-10 | Mead Johnson & Company | Alkylsulfonylphenoxypropanolamine derivatives |
JPS5936617B2 (en) * | 1976-03-05 | 1984-09-05 | 大塚製薬株式会社 | carbostyril derivatives |
CH619453A5 (en) * | 1976-03-17 | 1980-09-30 | Otsuka Pharma Co Ltd | |
US4235919A (en) * | 1977-07-21 | 1980-11-25 | Sandoz Ltd. | 1-(Indol-4-yloxy)-3-(2-substituted amino)-2-propanols and pharmaceutical use thereof |
DE2830211A1 (en) * | 1977-07-21 | 1979-02-01 | Sandoz Ag | SUBSTITUTED INDOL DERIVATIVES, THEIR PRODUCTION AND USE |
EP0002792A1 (en) * | 1978-01-03 | 1979-07-11 | Sandoz Ag | 3-Aminopropoxyaryl derivatives, their preparation and pharmaceutical compositions containing them |
DK267779A (en) * | 1978-06-27 | 1979-12-28 | Merck & Co Inc | PROCEDURE FOR THE PREPARATION OF N-ARALKYLAMINO-PROPOXYCYANOPYRIDINES |
CH636856A5 (en) * | 1978-07-17 | 1983-06-30 | Sandoz Ag | 4-(3-Aminopropoxy)indole derivatives, their preparation and medicines containing them |
DE2914166A1 (en) * | 1979-04-07 | 1980-10-23 | Beiersdorf Ag | ARYL-SUBSTITUTED FURANE AND METHOD FOR THEIR PRODUCTION |
ES480066A1 (en) * | 1979-04-28 | 1980-04-01 | Especialid Latin Medicam Unive | Procedure for obtaining 1- (4-chloro-alpha, alpha-dimethyl-benzene-etanalline) -2-oxy-3- (aricoxi) propanes. (Machine-translation by Google Translate, not legally binding) |
DE2943406A1 (en) * | 1979-10-26 | 1981-05-07 | Basf Ag, 6700 Ludwigshafen | AMINO DERIVATIVES OF 2-METHYL-5- (2-HYDROXYSTYRYL) -1,3,4-THIADIAZOL |
DE2944222A1 (en) * | 1979-11-02 | 1981-05-14 | Basf Ag, 6700 Ludwigshafen | Amino derivs. of 1,2-benzisothiazole - beta:sympatholytics suitable for the treatment of coronary heart disease, hypertonia and cardiac arrhythmia |
JPS568319A (en) * | 1980-03-26 | 1981-01-28 | Otsuka Pharmaceut Co Ltd | Antihistamine |
US4332787A (en) * | 1980-06-23 | 1982-06-01 | The Massachusetts General Hospital | Assay for beta-adrenergic antagonists and antibody therefor |
JPS5780321A (en) * | 1980-11-05 | 1982-05-19 | Otsuka Pharmaceut Co Ltd | Cardiotonic agent |
US4376125A (en) * | 1980-11-05 | 1983-03-08 | University Of Virginia Alumni Patents Foundation | Aminobenzlpropranolol and pharmaceutical preparation thereof |
EP0095454A3 (en) * | 1982-05-13 | 1985-04-03 | Gerot-Pharmazeutika Gesellschaft m.b.H. | Nuclens-substituted pyrogallol derivatives |
DE3301198A1 (en) * | 1983-01-15 | 1984-07-19 | Hoechst Ag, 6230 Frankfurt | N-Arylalkylamine-3-propoxypyridine derivatives, process for their preparation, pharmaceutical preparations containing them and their use |
US4517188A (en) * | 1983-05-09 | 1985-05-14 | Mead Johnson & Company | 1-Pyrimidinyloxy-3-hetaryl-alkylamino-2-propanols |
NZ214823A (en) * | 1985-01-15 | 1989-08-29 | Glaxo Group Ltd | 2-substituted-3,4-dihydroxyphenethylamino derivatives |
GB2192394A (en) * | 1986-07-11 | 1988-01-13 | Glaxo Group Ltd | Amine derivatives |
ES2070151T3 (en) * | 1988-08-10 | 1995-06-01 | Otsuka Pharma Co Ltd | CARDIOTONIC AGENTS. |
DE4040186A1 (en) * | 1989-12-20 | 1991-06-27 | Hoechst Ag | Use of 3-amino-propan-1,2-di:ol derivs. - as racemate, enantiomeric mixt. or pure enantiomer in treatment of diabetes mellitus |
DE4017019A1 (en) * | 1990-05-26 | 1991-11-28 | Hoechst Ag | USE OF SUBSTITUTED SS-HYDROXYETHYLAMINES AS POTENTIAL INGREDIENTS OF THE EXOENZYME OF MUSHROOMS |
ATE159009T1 (en) * | 1991-05-10 | 1997-10-15 | Rhone Poulenc Rorer Int | BIS MONO- AND BICYCLIC ARYL AND HETEROARYL DERIVATIVES WITH AN INHIBITING EFFECT ON THE EGF AND/OR PDGF RECEPTOR TYROSINKINASE |
EP0724561B1 (en) * | 1991-08-23 | 2004-04-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active arylalkyl amines |
US5763569A (en) * | 1991-08-23 | 1998-06-09 | The Brigham And Women's Hospital, Inc | Calcium receptor-active molecules |
CA2115828C (en) * | 1991-08-23 | 2011-09-20 | Edward F. Nemeth | Calcium receptor active molecules |
DE69333527T2 (en) * | 1993-02-23 | 2005-06-16 | Brigham & Women's Hospital, Inc., Boston | CALCIUM RECEPTACTIVE MOLECULES |
GB9312893D0 (en) * | 1993-06-22 | 1993-08-04 | Boots Co Plc | Therapeutic agents |
ZA967892B (en) * | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
-
1997
- 1997-04-04 AU AU26070/97A patent/AU726659B2/en not_active Expired
- 1997-04-04 PL PL329314A patent/PL191027B1/en unknown
- 1997-04-04 CA CA002251331A patent/CA2251331C/en not_active Expired - Lifetime
- 1997-04-04 DE DE69733649T patent/DE69733649T2/en not_active Expired - Lifetime
- 1997-04-04 SG SG9905132A patent/SG99290A1/en unknown
- 1997-04-04 NZ NZ332068A patent/NZ332068A/en not_active IP Right Cessation
- 1997-04-04 BR BR9708632-0A patent/BR9708632A/en not_active Application Discontinuation
- 1997-04-04 JP JP09536327A patent/JP2001501584A/en not_active Ceased
- 1997-04-04 EA EA199800913A patent/EA002984B1/en not_active IP Right Cessation
- 1997-04-04 US US08/832,984 patent/US6022894A/en not_active Expired - Fee Related
- 1997-04-04 WO PCT/US1997/005558 patent/WO1997037967A1/en active IP Right Grant
- 1997-04-04 EP EP97917848A patent/EP0901459B1/en not_active Expired - Lifetime
- 1997-04-04 IL IL12645897A patent/IL126458A/en not_active IP Right Cessation
- 1997-04-04 AT AT97917848T patent/ATE298739T1/en not_active IP Right Cessation
- 1997-04-04 CN CNB971953686A patent/CN1254465C/en not_active Expired - Lifetime
- 1997-04-08 CO CO97017849A patent/CO4820431A1/en unknown
- 1997-04-09 AR ARP970101400A patent/AR008586A1/en active IP Right Grant
- 1997-06-16 SA SA97180135A patent/SA97180135B1/en unknown
-
1998
- 1998-08-11 US US09/132,179 patent/US6521667B1/en not_active Expired - Fee Related
-
1999
- 1999-09-11 HK HK99103964A patent/HK1018899A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NZ332068A (en) | 2001-03-30 |
US6022894A (en) | 2000-02-08 |
EP0901459A1 (en) | 1999-03-17 |
AR008586A1 (en) | 2000-02-09 |
AU726659B2 (en) | 2000-11-16 |
IL126458A (en) | 2004-06-20 |
WO1997037967A1 (en) | 1997-10-16 |
HK1018899A1 (en) | 2000-01-07 |
SA97180135B1 (en) | 2006-06-12 |
PL191027B1 (en) | 2006-03-31 |
SG99290A1 (en) | 2003-10-27 |
CO4820431A1 (en) | 1999-07-28 |
JP2001501584A (en) | 2001-02-06 |
US6521667B1 (en) | 2003-02-18 |
BR9708632A (en) | 2000-01-18 |
DE69733649D1 (en) | 2005-08-04 |
EA199800913A1 (en) | 1999-06-24 |
AU2607097A (en) | 1997-10-29 |
PL329314A1 (en) | 1999-03-15 |
CA2251331C (en) | 2009-06-09 |
CN1221401A (en) | 1999-06-30 |
CN1254465C (en) | 2006-05-03 |
EA002984B1 (en) | 2002-12-26 |
ATE298739T1 (en) | 2005-07-15 |
EP0901459B1 (en) | 2005-06-29 |
DE69733649T2 (en) | 2006-05-18 |
IL126458A0 (en) | 1999-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2251331A1 (en) | Calcilytic compounds | |
HK1013251A1 (en) | Cosmetic formulations having keratolytic and/or anti-acne activity their preparation and use | |
AU3428393A (en) | Use of polyamines as ionic-channel regulating agents | |
CA2195213A1 (en) | Use of droloxifene for the treatment of cardiovascular diseases | |
AU3590897A (en) | Traveler's quarters | |
HUP9904047A3 (en) | N-arylsulfilimine compounds and their use as catalysts in the preparation of n-arylarylsulfonamide compounds | |
AU2466695A (en) | The use of famotidine and related compounds in the treatment of movement disorders | |
CA2279498A1 (en) | The use of levobupivacaine in paediatric surgery | |
AU6388494A (en) | Skin care composition | |
EP0736600A3 (en) | Use of an "immunodeficiency-virus suppressing lymphokine (ISL)" to inhibit the replication of viruses, in particular of retroviruses | |
AU9052991A (en) | Use of angiotensin ii antagonist in the treatment of infarction | |
AU9064191A (en) | Use of angiotensin ii receptor antagonists in the treatment of atheroma | |
GB9708067D0 (en) | Rapid and long lasting biocidal system and its use to the treatment of hard surfaces | |
AU2992492A (en) | The use of d-fenfluramine and fenfluramine compounds in the treatment of hypertension in insulin-resistant subjects | |
HUP9701205A3 (en) | Fungicide composition containing two triazole-derivatives as active ingredients and use thereof | |
NZ323282A (en) | N,n'-bridged bisindolylmaleimides and their use to prepare n,n'-bridged bisindolylmaleimides | |
IL133398A0 (en) | (s) 2-methylamino-2-phenyl - n-butyl 3,4,5 - trimethoxybenzoate and its application to the treatment of chronic pain | |
AU1485197A (en) | Diamines in the treatment of arrhythmia | |
GB2275191B (en) | Use of antifungal compounds in the treatment of skin disorders | |
EP0897988A4 (en) | Physiologically active substances tkr1785's, process for the preparation thereof, and microbe | |
RU95100244A (en) | DIRT FOR THE TREATMENT OF PATIENTS | |
HU9800623D0 (en) | Oral application of "(+)-o-demethyl-tramadol as analgesic active component | |
IL135168A0 (en) | Novel pharmaceutically active compounds, their preparation and use as ece-inhibitors | |
AU4448497A (en) | Novel 6 or 7 substituted analogues of swainsonine, processes for their preparation and their use as therapeutic agents | |
AU4886296A (en) | N-alkylpipecolic acid compounds, their preparation and use in the synthesis of levobupivacaine and analogues |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |